消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2021 CAG立场声明：丁溴东莨菪碱在胃肠内镜检查期间的应用

2021-10-12 加拿大胃肠病学协会 J Can Assoc Gastroenterol

胃肠内镜检查丁溴东莨菪碱

2021年10月，加拿大胃肠病学协会(CAG)发布了丁溴东莨菪碱在胃肠内镜检查期间的应用立场声明。丁溴东莨菪碱是一种常用于内镜手术期间诱导平滑肌松弛和减少胃肠道痉挛的毒蕈碱药物。

中文标题：

2021 CAG立场声明：丁溴东莨菪碱在胃肠内镜检查期间的应用

英文标题：

Canadian Association of Gastroenterology (CAG) Position Statement on the Use of Hyoscine- n-butylbromide (Buscopan) During Gastrointestinal Endoscopy

发布机构：

加拿大胃肠病学协会

发布日期：

2021-10-12

简要介绍：

2021年10月，加拿大胃肠病学协会(CAG)发布了丁溴东莨菪碱在胃肠内镜检查期间的应用立场声明。丁溴东莨菪碱是一种常用于内镜手术期间诱导平滑肌松弛和减少胃肠道痉挛的毒蕈碱药物。本文主要针对丁溴东莨菪碱在胃肠内镜检查期间的应用提供指导建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 CAG立场声明：丁溴东莨菪碱在胃肠内镜检查期间的应用.pdf)] GetToolGuiderByIdResponse(projectId=1, id=64cc91c002288613, title=2021 CAG立场声明：丁溴东莨菪碱在胃肠内镜检查期间的应用, enTitle=Canadian Association of Gastroenterology (CAG) Position Statement on the Use of Hyoscine- n-butylbromide (Buscopan) During Gastrointestinal Endoscopy, guiderFrom=J Can Assoc Gastroenterol, authorId=0, author=, summary=2021年10月，加拿大胃肠病学协会(CAG)发布了丁溴东莨菪碱在胃肠内镜检查期间的应用立场声明。丁溴东莨菪碱是一种常用于内镜手术期间诱导平滑肌松弛和减少胃肠道痉挛的毒蕈碱药物。, cover=https://img.medsci.cn/20211210/1639126349704_1608702.png, journalId=0, articlesId=null, associationId=716, associationName=加拿大胃肠病学协会, associationIntro=加拿大胃肠病学协会(CAG)成立于1962年，该协会现有成员1100多个，包括胃肠科医生，外科医生，儿科医生，基础研究者和护士等。协会的目的是进行消化道的健康和疾病研究，通过指导患者护理、教学、持续专业发展促进胃肠道科学发展，提倡并维护最高的道德标准。CAG注重教育职能，协会网站设有Physician Education栏目，为会员提供继续医学教育、培训项目等信息。 协会每年2月末都举办加拿大消化疾病周会议(CDDW)，分为临床和基础两个会场，参会人员包括胃肠病学、肝病学、内镜和胃肠外科等专业的医生和研究人员。CAG还注重患者教育，从首页可链接到加拿大消化道健康基金会(CDHF)为患者介绍消化系统疾病的相关知识。, copyright=0, guiderPublishedTime=Tue Oct 12 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年10月，加拿大胃肠病学协会(CAG)发布了丁溴东莨菪碱在胃肠内镜检查期间的应用立场声明。丁溴东莨菪碱是一种常用于内镜手术期间诱导平滑肌松弛和减少胃肠道痉挛的毒蕈碱药物。本文主要针对丁溴东莨菪碱在胃肠内镜检查期间的应用提供指导建议。</span></p>, tagList=[TagDto(tagId=60302, tagName=胃肠内镜检查), TagDto(tagId=119474, tagName=丁溴东莨菪碱)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=76, categoryName=胃肠外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=60302, guiderKeyword=胃肠内镜检查, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=6, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2702, appHits=60, showAppHits=0, pcHits=354, showPcHits=2642, likes=0, shares=4, comments=6, approvalStatus=1, publishedTime=Sat Dec 11 12:31:44 CST 2021, publishedTimeString=2021-10-12, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Fri Dec 10 16:58:15 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 21:08:14 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 CAG立场声明：丁溴东莨菪碱在胃肠内镜检查期间的应用.pdf)])
2021 CAG立场声明：丁溴东莨菪碱在胃肠内镜检查期间的应用.pdf
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2268393, encodeId=f69922683934a, content=与临床很密切，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55222648864, createdName=306222527, createdTime=Sun Jun 08 13:33:19 CST 2025, time=2025-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085415, encodeId=d4351085415bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a85549889, createdName=ms2000000182667314, createdTime=Wed Dec 29 12:59:35 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082350, encodeId=7c45108235081, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:39:05 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080175, encodeId=64c810801e5cf, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 15 07:01:27 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079662, encodeId=d69710e96629b, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=LFRRP6YqrAia0BryFmv6ibnA&s=100&t=1555426989, createdBy=79c45230339, createdName=刘晓捷, createdTime=Mon Dec 13 19:39:54 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2025-06-08 306222527

    与临床很密切，学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2268393, encodeId=f69922683934a, content=与临床很密切，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55222648864, createdName=306222527, createdTime=Sun Jun 08 13:33:19 CST 2025, time=2025-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085415, encodeId=d4351085415bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a85549889, createdName=ms2000000182667314, createdTime=Wed Dec 29 12:59:35 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082350, encodeId=7c45108235081, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:39:05 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080175, encodeId=64c810801e5cf, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 15 07:01:27 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079662, encodeId=d69710e96629b, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=LFRRP6YqrAia0BryFmv6ibnA&s=100&t=1555426989, createdBy=79c45230339, createdName=刘晓捷, createdTime=Mon Dec 13 19:39:54 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2021-12-29 ms2000000182667314

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2268393, encodeId=f69922683934a, content=与临床很密切，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55222648864, createdName=306222527, createdTime=Sun Jun 08 13:33:19 CST 2025, time=2025-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085415, encodeId=d4351085415bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a85549889, createdName=ms2000000182667314, createdTime=Wed Dec 29 12:59:35 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082350, encodeId=7c45108235081, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:39:05 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080175, encodeId=64c810801e5cf, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 15 07:01:27 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079662, encodeId=d69710e96629b, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=LFRRP6YqrAia0BryFmv6ibnA&s=100&t=1555426989, createdBy=79c45230339, createdName=刘晓捷, createdTime=Mon Dec 13 19:39:54 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2021-12-21 龙珠

    学习好资料！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2268393, encodeId=f69922683934a, content=与临床很密切，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55222648864, createdName=306222527, createdTime=Sun Jun 08 13:33:19 CST 2025, time=2025-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085415, encodeId=d4351085415bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a85549889, createdName=ms2000000182667314, createdTime=Wed Dec 29 12:59:35 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082350, encodeId=7c45108235081, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:39:05 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080175, encodeId=64c810801e5cf, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 15 07:01:27 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079662, encodeId=d69710e96629b, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=LFRRP6YqrAia0BryFmv6ibnA&s=100&t=1555426989, createdBy=79c45230339, createdName=刘晓捷, createdTime=Mon Dec 13 19:39:54 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2021-12-15 微探

    学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2268393, encodeId=f69922683934a, content=与临床很密切，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55222648864, createdName=306222527, createdTime=Sun Jun 08 13:33:19 CST 2025, time=2025-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085415, encodeId=d4351085415bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a85549889, createdName=ms2000000182667314, createdTime=Wed Dec 29 12:59:35 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082350, encodeId=7c45108235081, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:39:05 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080175, encodeId=64c810801e5cf, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 15 07:01:27 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079662, encodeId=d69710e96629b, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=LFRRP6YqrAia0BryFmv6ibnA&s=100&t=1555426989, createdBy=79c45230339, createdName=刘晓捷, createdTime=Mon Dec 13 19:39:54 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2021-12-13 刘晓捷

    受益匪浅

    0

相关指南

2021 AGA指南：SARS-CoV2检测以及疫苗接种后内镜检查（更新）

美国胃肠病协会(AGA,American Gastroenterological Association) · 2021-05-21

2020 ESGE/ESGENA立场声明：胃肠内镜检查和COVID-19流行

欧洲胃肠道内窥镜学会(ESGE,European Society of Gastrointestinal Endoscopy) · 2020-04-17

2019 GESA立场声明：胃肠内镜检查期间应用西甲硅油

澳大利亚胃肠病学会(GESA,Gastroenterological Seciety of Australia) · 2019-06-26

2018 ESGE/ESGENA立场声明：用于胃肠内镜检查的软式消化内镜及附件再处理

欧洲胃肠道内窥镜学会(ESGE,European Society of Gastrointestinal Endoscopy) · 2018-11-20

2018 ASGE指南：胃肠内镜检查期间感染控制

美国胃肠内镜学会(ASGE,American Society for Gastrointestinal Endoscopy) · 2018-03-21

2017 ASGE指南：胃肠内镜检查的镇静和麻醉

美国胃肠内镜学会(ASGE,American Society for Gastrointestinal Endoscopy) · 2017-12-23

拓展阅读

2017 SIED意见书：非麻醉医生胃肠内镜检查应用丙泊酚

意大利消化内镜学会(SIED,Italian Society of Digestive Endoscopy) · 2017-09-05

2017 ASGE指南：胃肠内镜检查的镇静和麻醉

美国胃肠内镜学会(ASGE,American Society for Gastrointestinal Endoscopy) · 2017-12-23

2018 ASGE指南：胃肠内镜检查期间感染控制

美国胃肠内镜学会(ASGE,American Society for Gastrointestinal Endoscopy) · 2018-03-21

2018 ESGE/ESGENA立场声明：用于胃肠内镜检查的软式消化内镜及附件再处理

欧洲胃肠道内窥镜学会(ESGE,European Society of Gastrointestinal Endoscopy) · 2018-11-20

2019 GESA立场声明：胃肠内镜检查期间应用西甲硅油

澳大利亚胃肠病学会(GESA,Gastroenterological Seciety of Australia) · 2019-06-26

2020 ESGE/ESGENA立场声明：胃肠内镜检查和COVID-19流行

欧洲胃肠道内窥镜学会(ESGE,European Society of Gastrointestinal Endoscopy) · 2020-04-17